No approved-drug candidate for pain agnosia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
RCSB Protein Data Bank · entry 7W9K · 2.2 Å · ligand O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine (P5S). Experimental structure, not a prediction.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Lara D. Veeken · 2005 · 147 citations · open access
Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy
AbstractOBJECTIVES: To determine the expression of mRNA encoding the proteoglycans aggrecan, versican, biglycan and decorin in mid-tendon samples of chronic painful Achilles tendinopathy and ruptured Achilles tendons, compared with normal tendons. METHODS: Total RNA isolated from frozen tendon samples (14 normal, 13 painful, 14 ruptured) was assayed by relative quantitative reverse transcription polymerase chain reaction for aggrecan, versican, biglycan and decorin mRNA, normalized using 18S rRNA. Differences between sample groups were tested by univariate analysis of variance with age as co-variate. RESULTS: In normal tendon samples expression of each of the proteoglycan mRNA decreased with increasing age. Decorin mRNA was the most highly-expressed of the proteoglycan mRNA, while versican mRNA expression was higher (3.8-fold) than that of aggrecan. In painful tendinopathy both aggrecan and biglycan mRNA expression increased (more than 10-fold and 5-fold, respectively) compared with normal tendon samples, but levels of versican and decorin mRNA were not significantly changed. In ruptured tendons the levels of aggrecan, biglycan and versican mRNA were not changed compared with normal tendon samples, but decorin mRNA decreased markedly. CONCLUSIONS: Increased aggrecan and biglycan mRNA expression in painful tendinopathy resembles the pattern in fibrocartilaginous regions of tendon, and may reflect an altered mechanical environment at the site of the lesion. Increased aggrecan mRNA expression may underlie the increase in glycosaminoglycan observed in painful tendinopathy.
https://doi.org/10.1093/rheumatology/kei152Clinical Journal of Pain · 2007 · 135 citations
Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey
AbstractBACKGROUND: Fabry disease is a multisystemic life-threatening lysosomal storage disorder caused by deficiency of alpha-galactosidase A. Symptoms of the disease may occur in different organs including kidney, heart, and the nervous system. OBJECTIVES: To evaluate the nature and prevalence of pain in a large cohort of patients with Fabry disease and to assess the effect of enzyme replacement therapy (ERT) with agalsidase alfa. METHODS: Retrospective analysis of the data of 752 patients with Fabry disease (393 females, 353 males) enrolled in the Fabry Outcome Survey, a multicentre database. RESULTS: The prevalence of pain in male patients was 81.4% (females 65.3%). Mean age at onset of pain was 14.8+/-1.0 year in males (females 19.8+/-1.4 y). Pain was most frequently reported in the hands (males 76%, females 60%) and feet (males 73%, females 52%), but often affected the whole body. Interference of pain with daily life was higher in females than in males, and was observed predominantly for general activities, mood, and normal work. Fifty-eight percent of the patients were on ERT with agalsidase alfa. At 24 and 36 months after commencement of ERT, pain severity classification shifted towards lower severity (P<0.05). Moreover, after 36 months, "average pain" and "pain now" were significantly reduced (P<0.05). CONCLUSIONS: Pain is one of the most prevalent symptoms in Fabry disease with onset early in childhood. ERT with agalsidase alfa significantly reduces pain in this debilitating disorder.
https://doi.org/10.1097/ajp.0b013e318074c986Reumatismo · 2014 · 88 citations · open access
Pain in fibromyalgia and related conditions
AbstractPain is the hallmark symptom of fibromyalgia (FM) and other related syndromes, but quite different from that of other rheumatic diseases, which depends on the degree of damage or inflammation in peripheral tissues. Sufferers are often defined as patients with chronic pain without an underlying mechanistic cause, and these syndromes and their symptoms are most appropriately described as "central pain", "neuropathic pain", "nonnociceptive pain" or "central sensitivity syndromes". The pain is particular, regional or widespread, and mainly relates to the musculoskeletal system; hyperalgesia or allodynia are typical. Its origin is currently considered to be distorted pain or sensory processing, rather than a local or regional abnormality. FM is probably the most important and extensively described central pain syndrome, but the characteristics and features of FM-related pain are similar in other disorders of particular interest for rheumatologists, such as myofascial pain syndromes and temporo-mandibular joint disorders, and there is also an intriguing overlap between FM and benign joint hypermobility syndrome. This suggests that the distinctive aspects of pain in these idiopathic or functional conditions is caused by central nervous system hypersensitivity and abnormalities. Pharmacological and non-pharmacological therapies have been suggested for the treatment of these conditions, but a multidisciplinary approach is required in order to reduce the abnormal cycle of pain amplification and the related maladaptive and self-limiting behaviours.
https://doi.org/10.4081/reumatismo.2014.767Chinese Medical Journal · 2006 · 46 citations · open access
The immune system: a new look at pain
AbstractOBJECTIVE: To review the relationship between the immune system and the mechanism of pain. Data sources Related researches published in the period of 1987-2005 were systematically reviewed. Study selection Articles about the immune system and pain were selected. Data extraction Data were mainly extracted from 74 articles which are listed in the reference section of this review. RESULTS: Pain was classically viewed as being mediated solely by neurons. However, growing evidence has showed the possible relationships between the immune system and the central nervous system. In this article, we reviewed the role of the immune system in the development of pain, together with the importance of the glia in this process. These findings suggest a novel approach to pain control in the future. CONCLUSIONS: The immune system plays a potential but important role in the development of pain.
https://doi.org/10.1097/00029330-200606010-00009Journal of the American Podiatric Medical Association · 1993 · 8 citations
Reflex sympathetic dystrophy syndrome
AbstractReflex sympathetic dystrophy syndrome is a troublesome, complex disorder that presents with chronic, unexplained aching or burning pain, the intensity of which is incommensurable with the original injury. Six diagnostic criteria have been described by Genant et al: pain and tenderness in the extremities; swelling of soft tissue; diminished motor function; trophic skin changes; vasomotor instability; and patchy osteoporosis. Currently, the most widely accepted etiology is an initial vasomotor reflex spasm occurring after an injury to the extremity, followed by a loss of vascular tone, persistent vasodilation, and rapid bone resorption.
https://doi.org/10.7547/87507315-83-5-276PubMed · 2023 · 4 citations
[Immediate analgesic effect of electroacupuncture combined with diclofenac sodium on acute gouty arthritis: a randomized controlled trial].
AbstractOBJECTIVE: To observe the immediate analgesic effect of electroacupuncture (EA) combined with diclofenac sodium on acute gouty arthritis (AGA). METHODS: points, Dadu (SP 2), Taichong (LR 3), Taibai (SP 3), Neiting (ST 44), Sanyinjiao (SP 6), Zusanli (ST 36) and Yinlingquan (SP 9) on the affected side, and Taichong (LR 3) and Zusanli (ST 36), Sanyinjiao (SP 6) and Yinlingquan (SP 9) were connected to electroacupuncture respectively, continuous wave, 2 Hz in frequency. The visual analogue scale (VAS) scores of pain before treatment and after 10 min, 2 h, 4 h and 6 h of treatment completion, joint tenderness and swelling scores before treatment and after 10 min and 6 h of treatment completion were compared, and the rate of diclofenac sodium addition within 24 h after treatment completion was recorded among the three groups. RESULTS: <0.05). CONCLUSION: Electroacupuncture combined with diclofenac sodium have a good immediate analgesic effect in the treatment of AGA, and have the advantages of small dosage of analgesic drugs and less adverse reactions.
https://doi.org/10.13703/j.0255-2930.20220907-k0001International Ayurvedic Medical Journal · 2020 · 1 citations · open access
THE ROLE OF AGNIKARMA IN MUSCULOSKELETAL PAIN MANAGEMENT
AbstractPain is a subjective phenomenon for the assessor but a bothersome and disturbing symptom to many. Many therapies and medicaments to combat pain exist in various medical disciplines. Agnikarma one such prom-ising treatment methodology which manage musculoskeletal pain very effectively. Musculoskeletal pain shares the maximum percentage of pain presentations to outpatient departments. Panchadhatu Shalaka and Madhu (Honey) are the most common and accessible instruments used for Agnikarma. Clinicians wit-nessed positive results for managing pain in disorders like Low back ache, Sciatica etc. Cost effectiveness, OPD basis treatment and instantaneous pain relief are the optimistic outcomes of Agnikarma therapy.
https://doi.org/10.46607/iamj2408122020Anesthesia & Analgesia · 2016 · 1 citations
Abstract PR327
AbstractBackground & Objectives: Worldwide there is extensive morbidity due to musculoskeletal pain. This is problematic in developing countries due to the high cost and access to therapy. Agnikarma is an ancient surgical treatment for pain (1). It involves thermal cauterization (first or second degree burn) delivered precisely to the trigger point in the area of allodynia. Advances in herbal cream for burns has facilitated a revival and re evaluation of this technique. Our objective was to document that the technique can improve pain management for patients. In addition we set out to establish a clinical evidence base that was appropriate to time and place. This environment is not suitable for a randomised trial but holds the potential to make a significant statement on efficacy nonetheless. We set up the global Agnikarma centre - www.globalagnikarma.com to offer the treatment. Materials & Methods: The international consultants (authors) experts in pain medicine and holistic medicine agreed a protocol whereby the same clinical information was collected on every patient at each visit setting up an extensive clinical database. Furthermore an extensive video library of pre and post treatment records was generated. Having learned the technique the presenting author offered the treatment to a specific group of patients in Ireland. These patients all had a diagnosis of chronic pain and had failed all conventional pain management.They all had graduated from a cognitive behavioural pain management programme. 100 patients were invited to visit the web site and self select for treatment. Results: We treated 14173 patients with 39658 procedures as of 21-2-2016 over a two year period. The case mix was 50% knee, 25% lumbar spine, 15% shoulder & neck and 10 % miscellaneous. The average number of treatment sessions is three (range 1-6) to achieve benefit. In Ireland the one year audit data for resistant chronic pain - 51 patients self selected, 25 were deemed suitable and completed 4 sessions. 76% had greater than 50 % pain relief, 80% had improved function, 30 % had improved sleep, 60 % stated that the benefit was still present at the end of the year, 80 % would have the procedure again. Conclusion: We have introduced a novel interventional pain therapy which offers hope to patients suffering from pain as it is simple efficacious and sustained. We have set up a transparent clinical data base complemented by a clinical video library which can be audited by interested parties. We have piloted a sample audit in resistant chronic pain patients where no efficacy would be anticipated in a totally different environment and documented benefit. There is now sufficient proof of concept for a more detailed investigation. References: 1. Sushruta Samhita. Disclosure of Interest: None declared
https://doi.org/10.1213/01.ane.0000492723.81475.70Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
